

Original Article

The Hand-Held Fan and the Calming Hand for People With Chronic Breathlessness: A Feasibility Trial



Flavia Swan, PhD, Anne English, MSc, Victoria Allgar, PhD, Simon P. Hart, PhD, and Miriam J. Johnson, MD
Wolfson Palliative Care Research Centre (F.S.), Allam Medical Building, Hull York Medical School (HYMS), University of Hull, Hull; Dove House Hospice (A.E.), Hull; Hull York Medical School (HYMS) (V.A.), Department of Health Sciences, University of York, Heslington, York; Respiratory Research Group (S.P.H.), Hull York Medical School, Castle Hill Hospital, Cottingham, Hull; and Wolfson Palliative Care Research Centre (M.J.J.), Hull York Medical School (HYMS), University of Hull, Hull, UK

Abstract

Context. The battery-operated hand-held fan (“fan”) and the Calming Hand (CH), a cognitive strategy, are interventions used in clinical practice to relieve chronic breathlessness.

Objective. To test the feasibility of a Phase III randomized controlled trial (RCT) evaluating the impact of the fan and/or CH compared with exercise advice alone for the relief of chronic breathlessness due to respiratory conditions.

Methods. A single-site, feasibility “2 × 2” factorial, nonblinded, mixed-methods RCT was performed. Participants randomly allocated to four groups: fan + exercise advice, CH + exercise advice, fan + CH + exercise advice, and exercise advice alone. Measures included recruitment, acceptability, data quality and study outcomes (baseline and day 28), modified Incremental Shuttle Walk Test (mISWT), recovery time from exertion-induced breathlessness, life-space questionnaire, General Self-Efficacy Scale, and breathlessness numerical rating scales. Willing participants and carers were interviewed at study end.

Results. Recruitment/acceptability/data completion: 53 people were screened, 40 randomized and completed (mean age 72 years (SD 9.8), 70% male). There were few missing data (mISWT, $n = 2$). Recovery time (seconds) from exertion-induced breathlessness showed most improvement for the fan; mean reduction from baseline -33.5 vs. CH mean increase from baseline 5.7 . This represents a recovery speed at day 28 (-20.4%) faster for the fan vs. 4.1% slower for the CH. Qualitative data indicated participants valued the faster recovery and identified the fan as a useful “medical” device but found the CH unhelpful.

Conclusion. A Phase III RCT is feasible. Mixed-methods data synthesis supports recovery time as a novel, meaningful outcome measure. *J Pain Symptom Manage* 2019;57:1051–1061. *Crown Copyright* © 2019 Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. All rights reserved.

Key Words

Breathlessness, nonpharmacological, fan, exercise, self-management, RCT, semistructured interviews

Introduction

People with progressive cardiorespiratory conditions frequently experience disabling chronic breathlessness that seriously affects daily life despite optimum treatment of their underlying disease.¹ It is associated with poor health outcomes: reduced quality of life,² restricted activities,³ emergency health care, and hospital admissions.⁴ Despite the widespread effects of

breathlessness, chronic breathlessness is often invisible to the clinician and therefore overlooked, leaving patients, carers, and family members to manage the symptom burden with little professional help.⁵

Management is modeled on a multidisciplinary, complex intervention that incorporates a range of pharmacological and nonpharmacological interventions.⁶ Nonpharmacological interventions promote self-efficacy,

Address correspondence to: Flavia Swan, PhD, Wolfson Palliative Care Research Centre, Hull York Medical School (HYMS), Allam Medical Building, University of Hull, Cottingham Road, Hull HU6 7RX, UK. E-mail: flavia.swan@hyms.ac.uk

Accepted for publication: February 18, 2019.

with some patients becoming expert in self-management.⁷ A clinical framework of “breathing,” “thinking,” and “functioning” can be used to target interventions that address vicious circles (ineffective ventilation, anxiety, reduced physical activity) that perpetuate the effects of breathlessness.⁸

Worse breathlessness is most commonly induced by physical exertion.⁹ Frequent episodes restrict normal daily activities, particularly, if the patient and/or family carer perceives breathlessness as an unpleasant or harmful experience to be avoided. A deconditioning spiral is thus perpetuated as lack of activity weakens peripheral muscles until breathlessness is eventually precipitated from the slightest physical effort.

Therefore, interventions that target exertion-induced breathlessness may improve the patient’s experience of everyday activities and prevent exercise avoidance. Strong evidence supports the role of exercise and activity to reduce the impact of breathlessness,¹⁰ yet the patient’s misperception of the symptom as inherently dangerous may act as a disincentive to continue activities and reduce adherence to a rehabilitation program^{11,12}; however, the strength of evidence varies for nonpharmacological interventions and is sparse for some, an issue highlighted by previous Cochrane review (update in preparation).¹³

Two interventions used in clinical practice are the battery-operated hand-held fan (“fan”) and the Calming Hand (CH) (a cognitive strategy [[online supplementary diagram](#)]).¹⁴ Growing evidence suggests that cool airflow delivered from the fan can decrease breathlessness.¹⁵ Stimulation of facial, nasal, or upper airway flow receptors may modulate the central perception of breathlessness and decrease neural respiratory drive.^{16–18} Little or no effectiveness evidence exists for the CH, and little is known about possible mechanisms for benefit but is thought to target cognitive-emotional pathways to modulate the central perception of breathlessness. Both interventions are inexpensive, readily available, easy to use, and portable, providing the patient and carer with an intervention suited for self-management strategies for exertion-induced breathlessness.

We investigated the feasibility of conducting a Phase III randomized controlled trial (RCT) to test the effectiveness of fan, CH, or both compared with self-management and exercise advice alone for the relief of exertion-induced breathlessness in people with chronic breathlessness due to respiratory disease.

Methods

Study Design

The Calming Hand and Fan Feasibility (CHAFF) was a mixed-methods study: Phase II, single-site, “2 × 2” factorial, unblinded randomized controlled trial

and qualitative semistructured interviews of participants and their carers. Potentially eligible participants were approached and screened by the patient’s usual clinician at an outpatient appointment at Castle Hill Hospital, Hull. Eligible patients were consenting adult respiratory outpatients with Medical Research Council breathlessness scale grade ≥ 3 ¹⁹ due to an optimally treated respiratory disease. Patients were excluded if they had used the fan or CH within the previous two weeks, had trigeminal nerve damage, or were too unwell to complete study procedures. Carers (if present) of the patient participants were also invited to consent to providing data about carer experience. Participants were allocated to exercise advice alone or with the addition of the fan, CH, or both, according to a block randomization schedule generated by a web-based random number sequence generator using a 1:1:1:1 ratio. This was managed by the Hull Clinical Trials Unit, who had access to sequentially numbered, opaque, sealed envelopes. The allocation was concealed from the study investigators, although once randomized, blinding was not possible. Measures were taken at baseline and again at day 28. Fidelity of patient adherence was assessed by fan and/or CH use at day 28. Participants and their carers were invited to take part in a semistructured interview at day 28.

Interventions

Participants were randomized after completion of all baseline measures. The intervention was delivered after randomization during one visit to the Respiratory Clinical Trials Unit at Castle Hill Hospital, Hull. The intervention was provided by an academic physiotherapist researcher. All four groups received one-hour face-to-face individual training in standardized breathlessness self-management and exercise advice. All participants were given an information leaflet for use at home. This was adapted with permission from the Cambridge Breathlessness Intervention Service leaflets,²⁰ available online and contained guidance on breathing control, recovery positions from breathlessness, activity pacing, and exercise advice.

Participants allocated to the CH and/or fan were instructed how to use the intervention(s) and encouraged to use whenever they felt breathless during the 28-day study period. A three-flexible blade, high-flow, plastic fan was used. Their information sheets included instruction on how to use the CH and/or fan depending on allocation. Intervention components delivered were documented in the clinical record of each participant.

Study Assessments and Outcomes

All study measures were assessed at baseline (day 0) and at 4 weeks (day 28). The same researcher who was not blinded to group assignment collected all the

outcome data and conducted the qualitative interviews at study end.

At baseline, clinical demographic data about age, sex, diagnosis, oxygen therapy, mobility aids, carer status, and the Charlson Comorbidity Index were collected.

The feasibility outcomes were as follows:

- Recruitment rate, screening/consent ratio, randomization, and attrition
- Data quality including patterns and proportions of missing data
- Baseline variance of the candidate outcome measures to estimate sample size for a Phase III trial:

Exercise and Activity. Modified Incremental Shuttle Walk Test (mISWT) distance, a standardized incremental field walking test that provokes a symptom-limited maximal exercise performance.^{21,22} The mISWT followed standard procedures.²¹ Life-space questionnaire, a measure of spatial mobility according to the level of movement a patient is able to make away from home with or without assistance and/or equipment.^{23–25}

Self-Efficacy. General Self-Efficacy Scale (GSES) (patient and carer), a 10-item, five-point scale (0 = not at all true and 4 = exactly true) measure of a person's beliefs about their capability to handle new or difficult tasks.^{26,27}

Breathlessness Assessment. An 11-point numerical rating scale (NRS; 0 = none and 10 = worst possible) was used to measure breathlessness,²⁸ intensity on average and at its worst over the previous 24 hours, the unpleasantness of and distress due to breathlessness, and intensity at each timepoint (every minute) during recovery time from maximal exertion-induced breathlessness during mISWT. Recovery time was defined as the time taken for the participant to return to their baseline NRS breathlessness intensity value from the point of maximal breathlessness after the ISWT.

Carer Assessment. Zarit carer burden short-form, a six-item, five-point scale (0 = never and, 4 = nearly always) that measures carer burden.^{29,30}

Interviews. Willing participants and carers were interviewed after study end (day 28). Participants were purposively sampled to include all participants from all four study arms (age, sex, diagnosis, and presence of carer) and to gain maximum variation. A topic guide was developed from the literature and research team experience to explore 1) the participant and carer experience of using the fan and CH (or not) and

the impact on the self-management of breathlessness, daily activities, and exercise and 2) the feasibility and acceptability of study participation including design and outcome measures. Interviews were conducted at the participant's home individually and/or as a carer dyad. All interviews were audio-recorded and transcribed verbatim.

The quantitative data are reported according to CONSORT guidelines,³¹ and the intervention according to the TIDIER checklist.³²

Ethics

Human Research Ethics approvals, including for the method of consent, and institutional permissions were obtained before recruitment (Leeds West Ethics committee, 12/YH/0410, 12/09/2012). The study protocol was registered ISRCTN40230190.

Sample Size

It was considered that 40 participants were sufficient to address the feasibility questions and inform the sample size for a Phase III RCT.³³

Statistical Analysis

All randomly assigned participants were included in the intention-to-treat analysis. As a feasibility study, the following descriptive analyses were conducted using SPSS (IBM SPSS Statistics for Windows, version 22.0, released 2013; IBM Corp, Armonk, NY):

- Descriptive analysis of recruitment
- Descriptive analysis on the completion of endpoints
- Calculation of the variance of change associated with the study outcome measurements.

Findings were not adjusted for baseline values. Missing data were not imputed.

Qualitative Analysis

Qualitative interviews were imported into NVivo, version 7. Thematic analysis was used following a process of immersion in data, line-by-line coding, grouping of codes into initial themes, and then generation of major themes.³⁴ Four interview transcripts were independently coded by two researchers, F. S. and M. J. J. They then formulated a working coding framework that was used by F. S. to systematically code, develop, and organize the data set into relevant categories with appropriate examples to illustrate the relevance to the research questions.

Mixed-Methods Data Synthesis

A convergent design used concurrent quantitative and qualitative data collection followed by separate analyses of the data types, before integration and

triangulation of the data set at the interpretative stage of the study.³⁵

Results

Participant Characteristics

Recruitment took place for 20 months during December 2012 and December 2014 (researcher was on leave between September 2013 and December 2013). Forty participants were randomized (mean age 72 years [SD 9.8], range 53–91; 28 [70%] males). Study flow can be seen in Figure 1. Baseline characteristics are summarized in Table 1. Of note, breathlessness measures, particularly distress and worst intensity over the past 24 hours, were better in the groups allocated to CH. Most participants (22 [55%]) had idiopathic pulmonary fibrosis (IPF), followed by chronic obstructive pulmonary disease in 12 (30%) participants. All participants had comorbid disease with three-quarters having a Charlson Comorbidity Index score of ≤ 2 . Baseline characteristics were generally balanced across the four arms, apart from

participants with IPF, who were allocated to exercise advice (7 [70%]) and exercise advice & CH (9 [90%]). Interestingly, carers in the fan & CH group had less burden and better GSES score. All participants received all components of the intervention.

Feasibility Outcomes

The recruitment rate averaged 2.0/month. Of 53 participants screened, 13 (24%) were excluded; two (4%) were ineligible (one cognitive impairment and one recent use of fan), and 11 (20%) declined to participate. Reasons for not participating were carer duties 1 (9%), hospitalization 1 (9%), other comorbidity problems 4 (36.5%), participants felt the study was too much 4 (36.5%), and no transport 1 (9%).

Data Completion

Forty participants were randomized, and 40 completed the trial. All study measures were completed by all participants apart from 2 (5%) participants who did not take part in a mISWT on day 28. However, baseline mISWT data from 13




Fig. 1. CONSORT flow diagram.³¹ CH = Calming Hand; mISWT = modified Incremental Shuttle Walk Test.

Table 1
Demographic Characteristics of Study Groups at Baseline

Demographic Data	Exercise Advice (<i>n</i> = 10)	Fan & Exercise Advice (<i>n</i> = 10)	CH & Exercise Advice (<i>n</i> = 10)	Fan & CH & Exercise Advice (<i>n</i> = 10)	Total (<i>N</i> = 40)
Age in years	70 (11.2), 53–86	70 (7.2), 61–84	79 (12.1), 59–91	71 (5.9), 56–71	72 (9.8), 53–91
Gender: Male	6 (60%)	8 (80%)	7 (70%)	7 (70%)	28 (70%)
Primary diagnosis					
COPD	1 (10%)	5 (50%)	1 (10%)	5 (50%)	12 (30%)
Pulmonary fibrosis	7 (70%)	3 (30%)	9 (90%)	3 (30%)	22 (55%)
Others	2 (20%)	2 (20%)	0 (0%)	2 (20%)	6 (15%)
Charlson Comorbidity Index score					
1 point	5 (50%)	5 (50%)	6 (60%)	4 (40%)	20 (50%)
2 points	3 (30%)	3 (30%)	2 (20%)	2 (20%)	10 (25%)
3 points	1 (10%)	2 (20%)	1 (10%)	4 (40%)	8 (20%)
4 points	1 (10%)	0 (0%)	1 (10%)	0 (0%)	2 (5%)
NRS intensity average last 24 hours	5.0 (2.11) 2–8	5.5 (1.43) 4–8	4.7 (1.77) 2–8	4.8 (1.13) 3–7	5.0 (1.62) 2–8
NRS distress average last 24 hours	4.8 (3.26) 0–9	5.6 (2.55) 0–9	3.7 (3.37) 0–9	3.3 (2.63) 0–8	4.3 (3.0) 0–9
NRS unpleasantness average last 24 hours	6.1 (2.68) 1–9	6.3 (2.16) 3–10	5.7 (2.26) 3–9	5.9 (2.18) 3–9	6.0 (2.25) 1–10
NRS intensity at worst last 24 hours	7.3 (1.7) 3–9	7.8 (1.32) 5–9	5.9 (2.28) 3–9	6.9 (1.66) 4–9	6.9 (1.85) 3–9
NRS distress at worst last 24 hours	6.1 (4.04) 0–10	7.0 (2.94) 0–10	4.1 (3.41) 0–9	4.3 (3.13) 0–9	5.3 (3.49) 0–10
Life-space questionnaire score	54.45 (24.74), 20–100	60.85 (22.69), 20–96	47.05 (13.9), 29–69	55.5 (19.37), 12–78	54.46 (20.4), 12–100
GSES	30.30 (5.44), 19–38	28.8 (6.53), 21–38	31.7 (6.31), 19–40	33.3 (4.90), 24–40	31.03 (5.85), 19–40
Recovery time mISWT (seconds)	179.0 (69.14), 98–303; MD = 3	164.0 (70.18), 90–291; MD = 4	140.29 (36.75), 91–201; MD = 3	163.57 (47.44), 85–232; MD = 3	161.63 (55.57), 85–303; MD = 13
mISWT distance (meters)	192.86 (138.05), 70–430; MD = 3	126.67 (81.65), 30–210; MD = 4	121.43 (90.26), 40–300; MD = 3	187.14 (85.97), 80–290; MD = 3	158.15 (102.02), 30–430; MD = 13
Zarit carer burden	8.5 (4.95), 5–12 (<i>n</i> = 2)	8 (3.56), 3–11 (<i>n</i> = 4)	7.25 (4.19), 1–10 (<i>n</i> = 4)	3.5 (3.0), 0–6 (<i>n</i> = 4)	6.57 (3.89), 0–12 (<i>n</i> = 14)
Carer GSES	33 (2.83), 31–35 (<i>n</i> = 2)	33.5 (3.11), 30–37 (<i>n</i> = 4)	32.5 (2.89), 30–35 (<i>n</i> = 4)	35.0 (3.56), 31–38 (<i>n</i> = 4)	33.57 (2.95), 30–38 (<i>n</i> = 14)

MD = missing data; *n* = number of participants; GSES = General Self-Efficacy Scale; mISWT = modified Incremental Shuttle Walk Test; NRS = numerical rating scale; COPD = chronic obstructive pulmonary disease; fan = hand-held fan; CH = Calming Hand.
Values are mean (SD), range or *n* (%).

participants (33%) were excluded due to a protocol deviation (baseline mISWT and recovery time collected after delivery of intervention in error). 14 carers were recruited and 13 (92%) completed the study. Data were missing from one carer who was unable to attend the day 28 appointment.

Outcomes

Table 2 summarizes the main outcomes for the four study arms at day 28 and the comparison of the mean change (day 28 minus baseline) and percentage between the groups for the potential Phase III outcome measures. Recovery time after the mISWT and the mISWT distance were the only outcomes that signaled usefulness for a Phase III trial. Recovery time (seconds) was fastest in the fan groups. Distress due to breathlessness improved by more in the CH groups.

The mISWT distance (meters) increased in both groups allocated to the fan; mean changes from baseline were 55.33 (44%) fan & exercise advice and 31.86 (17%) fan & CH & exercise advice. In contrast, the CH & exercise advice group showed only slight improvement; 18.57 (15%) and the walking distance decreased in the exercise advice group (−19.53, −11%).

Improvements in carer outcomes were of note in the fan & CH & exercise advice arm only; mean change from baseline Zarit burden 1.75; (5%) and GSES 0.25; (7.1%).

Overall, all 20 (100%) participants allocated to a fan arm were still using it on day 28, and 15 (75%) said they used it every day. In contrast, although 18 (90%) of those allocated to a CH arm were still using it at day 28, only 8 (40%) said they used it every day. Of interest, those allocated to CH were more likely to use it every day if this was their sole intervention (CH only − 6 (60%) daily use vs. CH and fan − 2 (20%) daily use)

Semistructured Interviews

A purposive sample of 11 participants and five carers took part in semistructured interviews. All interviews apart from one patient/carer dyad were conducted individually at home. The four study arms were represented with at least two participants and one carer from each arm; seven participants and three carers had had experience of the fan, and six participants and two carers had had experience of the CH. Overall, participants found the fan acceptable partly because of ease of use, and partly because they perceived benefit. The CH was largely dismissed in terms of acceptability.

The following four key themes were generated from the data (See Table 3 for Illustrative quotes).

The Fan Helps Recovery From Breathlessness. Participants consistently suggested that one of the main benefits of using the fan was helping recovery from episodes of breathlessness. This influenced how participants used the device as it was considered an extra tool that could easily be tailored to their daily breathlessness needs at any time or in any location.

The Fan Supports Exercise and Activity. This helped promote self-efficacy and participants felt more confident about self-managing their exertional breathlessness such that they were able to continue or even try activity that they had not previously thought possible or had learned to avoid.

The Fan Was Used Like a Medical Device. The value of the intervention was reflected in the way participants likened their use of the fan to a medical device, such as a replacement for a Ventolin inhaler or an adjunct between nebulizers.

The CH Was Considered Common Sense and Already Known. In contrast the CH was perceived as common sense and of little help managing breathlessness. Participants stated that the CH was a strategy that they had already tried in the past and as such it was nothing new. They described infrequent use to the extent of disregard.

Discussion

It is feasible to conduct a Phase III RCT in terms of recruitment, data completion, and acceptability of study procedures and measures; however, the mixed-methods data synthesis supports a future test of effectiveness of the fan, particularly during recovery from exertion-induced breathlessness, but gives a less clear signal for the CH. Recovery time showed a quantitative signal of activity with the fan and was identified by participants as a particular and important benefit of the fan. Although there was only a small change in terms of recovery time, this was discernible as welcome by the patient; this benefit from the fan was seen as an important factor in breathlessness self-management³⁶ and contributed to its acceptability to the participants. Participants described how the fan enabled them to do more physical activity, sufficient to restore lost activities of daily living such as shopping or hobbies such as fishing.

Quantitative data showed reduction in average daily distress due to breathlessness with the CH but did not indicate benefit in either unpleasantness, or intensity, or worst distress in the past 24 hours. Worst distress is likely to be related to exertion, and it may be that the

Table 2
Patient and Carer Outcome Measures at Day 28, Mean Change From Baseline, Absolute and Percentage

Patient Outcome Measures	Exercise Advice (n = 10)		Fan & Exercise Advice (n = 10)		CH & Exercise Advice (n = 10)		Fan & CH & Exercise Advice (n = 10)	
	Day 28	Mean Change; Absolute, %	Day 28	Mean Change; Absolute, %	Day 28	Mean Change; Absolute, %	Day 28	Mean Change; Absolute, %
NRS intensity <i>average last 24 hours</i>	5.2 (1.99), 1–8 MD = 0	0.2; 4%	6.1 (2.23), 3–10 MD = 0	0.6; 10.9%	4.8 (2.04), 2–9 MD = 0	0.1; 2.1%	4.9 (2.56), 1–8 MD = 0	–0.1; –2%
NRS distress <i>average last 24 hours</i>	5.2 (2.3), 2–8 MD = 0	0.4; 8.3%	5.3 (3.65), 0–10 MD = 0	–0.3; –5.3%	3.1 (2.02), 0–7 MD = 0	–0.6; –16.2%	3.8 (3.15), 0–10 MD = 0	–0.5; –11.6%
NRS unpleasantness <i>average last 24 hours</i>	5.9 (1.91), 3–9 MD = 0	–0.2; –3.2%	5.8 (2.53), 1–10 MD = 0	–0.5; –7.9%	6.2 (2.20), 3–10 MD = 0	0.5; 8.7%	4.7 (2.75), 0–10 MD = 0	–1.2; –20.3%
NRS intensity <i>at worst last 24 hours</i>	6.7 (1.34), 5–9 MD = 0	–0.6; –8%	7.5 (2.59), 2–10 MD = 0	–0.3; –3.8%	6.8 (2.25), 3–10 MD = 0	0.9; 15.2%	5.8 (2.53), 2–10 MD = 0	–1.1; –15.9%
NRS distress <i>at worst last 24 hours</i>	6.1 (2.47), 2–9 MD = 0	0.0; No change	6.5 (3.44), 0–10 MD = 0	–0.5; –7.1%	4.1 (2.99), 0–9 MD = 0	0.0; No change	4.9 (3.41), 0–10 MD = 0	–0.6; –11.3
Life-space questionnaire	54.0 (24.21), 25–100 MD = 0	–0.45; –0.8%	64.05 (19.23), 32–84 MD = 0	3.2; 5.2%	55.2 (14.67), 35–76 MD = 0	8.15; 17.3%	61.05 (27.06), 20–100 MD = 0	5.55; 10%
General Self-Efficacy Scale (GSES)	32.0 (5.96), 20–40 MD = 0	1.7; 5.6%	31.9 (4.36), 28–40 MD = 0	3.1; 10.8%	31.8 (4.96), 23–40 MD = 0	0.1; 0.3%	32.4 (4.40), 22–40 MD = 0	–0.9; –2.9%
Recovery time (seconds)	152.56 (41.45), 111–224 MD = 1	–26.44; –14.7%	130.5 (64.60), 74–305 MD = 0	–33.5; –20.4%	146.0 (38.88), 89–200 MD = 1	5.71; 4.1%	123.30 (24.93), 85–160 MD = 0	–40.27; –24.9%
mISWT distance (meters)	173.33 (124.9), 60–470 MD = 1	–19.53; –10.8%	182.0 (103.69), 50–340 MD = 0	55.33; 43.7%	140.0 (84.41), 30–310 MD = 1	18.57; 15.3%	219.0 (93.39), 120–410 MD = 0	31.86; 20.1%
Carer outcome measures	Exercise Advice (n = 2)		Fan & Exercise Advice (n = 4)		CH & Exercise Advice (n = 3)		Fan & CH & Exercise Advice (n = 4)	
	Day 28	Mean Change; Absolute, %	Day 28	Mean Change; Absolute, %	Day 28	Mean Change; Absolute, %	Day 28	Mean Change; Absolute, %
Zarit carer burden	10.0 (1.41), 9–11 MD = 0	1.5; 17.6%	8.75 (6.5), 0–15 MD = 0	0.75; 9.3%	5.00 (6.08), 1–12 MD = 1	–2.25; –31%	3.75 (2.63), 0–6 MD = 0	0.25; 7.1%
Carer GSES	32.5 (3.54), 30–35 MD = 0	–0.5; 1.5%	31 (4.69), 25–36 MD = 0	–2.5; –7.5%	32.67 (4.62), 30–38 MD = 1	0.17; 0.5%	36.75 (2.06), 35–39 MD = 0	1.75; 5%

n = number of participants; NRS = numerical rating scale; GSES = General Self-Efficacy Scale; mISWT = modified Incremental Shuttle Walk Test; MD = missing data. Values are mean (SD), range.

Table 3
Illustrative Quotes

Fan helps with recovery

- P18: "I do not know why I started cos. I wasn't exerting me-self as such I don't know why I started sorta gasping and I thought right fan and after a few seconds back to normal."
- P19: "I'll just sit ... put the fan six to eight inches away from me face on an angle so if I want it to go up me nose as well I can ... I find coupla minutes it does take the breathlessness down."
- P24: "the recovery is quicker ... it's fifty percent, I believe the air is being pushed in and fifty percent. I'm confident as to what's happening so I calm down quicker."

Fan supports activity and exercise

- P9: "I can walk round when I take the fan ... which I find very nice as I have never done it ... this is a really big change ... I can walk round [the shop] I can look at everything and I can read everything and it's wonderful."
- P11: "I've been going a bit further just recently since I've had me fan thing."
- P19: "Got me fan in me pocket and I've got me inhaler in me pocket so that I know if I ever go anywhere I've got more, more bases covered now I've got me fan as well."
- P24: "So you're hoping to go fishing again?" A: "with me son next, next week, and it'll be the first time in three years ... and that'll be [points to fan] going with me in me fishing bag."

Fan is used like a medical device

- P10: "I carry it around with me and I'll use it you know because I feel a bit out of puff because it's between nebulizers, I can't take too many nebulizers so that acts as a prop in-between."
- P12: "I've been using the fan instead of Ventolin."
- P17: "a little instrument or a tool you know ... it's a functional thing, it is a bit of equipment, not an idea yeah? You feel, once it's switched on it is a physical thing, you can feel the effect of it."
- P24: "Now I have the alternative, i.e., the fan, whereas I used to grab me inhaler and have two puffs, wait and hope something gets better; instead of that I get the fan ... I'm not using my inhaler half as much as I did."

Calming Hand is common sense and things already known

- P10: "What do you get with the Calming Hand?" A: "Nothing." Q: Nothing? A: "No the Calming Hand are things I do myself any how if I feel very breathless ... so that's nothing really new."
- P15: "The Calming Hand ... how did you find that?" A: "Well, common sense, its common sense."
- P17: "The Calming Hand, I didn't think it was really of much value ... I think I could find a lot of better ways of calming me-self down."
- P24: "I stopped doing the Calming Hand thing 'cos to me I don't need to do that to know there's a list to go through."

CH is less useful in recovery where a fan is simpler to use under these circumstances.

The recovery time data demonstrated a rapid return to baseline breathlessness score; all participants fully recovered from maximal exertional breathlessness in less than three minutes on average, and no longer than five, even after a walking test to maximal breathlessness. These figures are consistent with results from people with intrathoracic cancer (median 4 [IQR 2–5] minutes)³⁷ and indicate that patients with a diagnosis of chronic obstructive pulmonary disease, IPF, or asthma experience a similar rapid recovery from exertional breathlessness. This is clinically relevant information to reassure patients that exertion-induced breathlessness usually recovers quickly, countering beliefs that breathlessness is harmful.

Implications for Clinical Practice

The fan is a valuable component of breathlessness management that is pragmatic and easy to administer.^{15,36,38–40} Fear of breathlessness is a significant obstacle to exertion and exercise in people with chronic breathlessness and is a recognized factor in nonattendance of and drop-out from rehabilitation programs.^{12,41} If the fan shortens recovery time and improves patient confidence, this may help reduce the vicious circle of deconditioning through exercise avoidance. It may also be useful to help

adherence to pulmonary rehabilitation and long-term maintenance of outcomes.

The other important potential use for the fan is for breathlessness crisis, often exacerbated by anxiety and helplessness. "Fan to face" is already recommended as part of a breathlessness crisis plan.⁴² One-third of patients with acute-on-chronic breathlessness attending the emergency departments are discharged without need for hospital admission.⁴ As many of such attendances occur out of office hours when usual clinicians are unavailable⁴ and panic can be a greater risk,⁷ the fan as a self-management strategy usable by patients and family carers may be of value to increase perceived control over breathlessness, particularly if used as a medical device. Indeed the qualitative findings suggest a useful role for the fan with "out of the blue" breathlessness (P18), a breathlessness category known to cause severe distress and initiate help-seeking.⁷

Such self-efficacy is an important concept⁴³ and links to how effectively patients manage difficult symptoms with their quality of life.⁴⁴ Self-efficacy in coping with a breathlessness crisis is an important factor in avoiding emergency department presentation.⁷ The patient's experience of performance success or failure will likely validate or undermine their capabilities to cope with a given activity or situation. Significant improvements in the Chronic Respiratory Questionnaire's breathlessness self-mastery domain were seen with a complex

intervention for breathlessness management that included the fan.⁴⁵ Feasibility data have also indicated that the fan helps patients regain control and improve self-confidence to manage breathlessness by integrating into their daily activities and offering them a device that can be tailored to particular situations.³⁹

Implications for Future Research

Although further value of information of a Phase III trial of the fan as an isolated component for the benefit of breathlessness in everyday life is unlikely,³⁹ confirming its specific benefit on recovery time would be useful. If confirmed, this places the fan firmly as a tool to help improve daily physical activity, attendance and adherence to rehabilitation programs, and as an adjunct to breathlessness crisis management.

The lack of signal with CH may be because the trial was not designed to discard the null hypothesis; however, given the strong comments from the qualitative study and the lack of other literature to support effectiveness or to delineate possible mechanisms of action, these data do not support further study where recovery from exertion-induced breathlessness is the primary outcome. It may benefit distress due to breathlessness in general, and further work should be directed here rather than as a recovery measure.

Limitations

The same person delivered the interventions and collected the outcome data, which could have added to the reporting bias resulting from the lack of blinding. In addition, as participants did not perform a training mISWT, any change in mISWT distance at day 28 may represent learning²²; however, 1) these sources of bias will be consistent across all four study arms and 2) the aim of this feasibility study was to inform the design of a Phase III RCT rather than evaluate effectiveness. The exclusion of 13 baseline mISWTs and breathlessness recovery measurements reduce the data anticipated for analysis. Therefore, although the aim was to perform a sample size calculation, this was deemed inappropriate as the estimate would have relied on too few data or would have involved combining data from two of the study arms: fan & exercise advice and fan & CH & exercise advice. Consequently, further feasibility data are recommended to inform a more precise estimate for a future test of the fan.

The lack of IPF patients in either fan group might be important, if there is differential response to the fan or CH by diagnosis; however, the authors are unaware of any published observations with this regard.

Our choice of a single face-to-face training session was made pragmatically aiming to minimize participant burden as our recruitment pathway was likely to lead to a significant proportion of people with IPF;

however, although their prognosis is similar to cancer, there are no data to confirm the effectiveness of a single session as there is for cancer.⁴⁶ This should be reviewed in the design on a subsequent trial.

Finally, a qualitative study is not designed to provide generalizable data. The semistructured interview is inevitably influenced by the social interaction between the researcher and participant. Patients and carers may say what they think the researcher wanted to hear about the interventions in an attempt to please, although they did not seem to be constrained in reporting their adverse views about the CH; however, their views on cognitive interventions, rather than ones that can be more easily understood in a medical model (it was apparent that they viewed the fan in the same way as a medical device), may reflect regional and demographic culture and not be found in other areas.

Conclusion

A future Phase III RCT to test the fan is feasible. Further feasibility data are recommended to accurately inform the sample size calculation. Mixed-methods data synthesis supports recovery time as a novel, meaningful outcome measure. The data do not support the use of the CH as a recovery measure.

Disclosures and Acknowledgments

The authors declare that there is no conflict of interest. This study was funded as part of a University of Hull PhD studentship (Flavia Swan).

References

1. Johnson MJ, Currow DC. Chronic refractory breathlessness is a distinct clinical syndrome. *Curr Opin Support Palliat Care* 2015;9:203–205.
2. Currow DC, Dal Grande E, Ferreira D, Johnson MJ, McCaffrey N, Ekström M. Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. *Thorax* 2017;72:1151–1153.
3. Smith AK, Currow DC, Abernethy AP, et al. Prevalence and outcomes of breathlessness in older adults: a National Population study. *J Am Geriatr Soc* 2016;64:2035–2041.
4. Hutchinson A, Pickering A, Williams P, Bland JM, Johnson MJ. Breathlessness and presentation to the emergency department: a survey and clinical record review. *BMC Pulm Med* 2017;17:1–7.
5. Hutchinson A, Barclay-Kling N, Galvin K, Johnson MJ. Living with breathlessness: a systematic literature review and qualitative synthesis. *Eur Respir J* 2018;51.
6. Bausewein C, Schunk M, Schumacher P, Dittmer J, Bolzani A, Booth S. Breathlessness services as a new model

- of support for patients with respiratory disease. *Chronic Respir Dis* 2017;15:48–59.
7. Luckett T, Phillips J, Johnson M, et al. Insights from Australians with respiratory disease living in the community with experience of self-managing through an emergency department ‘near miss’ for breathlessness: a strengths-based qualitative study. *BMJ Open* 2017;7.
 8. Spathis A, Booth S, Moffat C, et al. The Breathing, Thinking, Functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. *NPJ Prim Care Respir Med* 2017;27:27.
 9. Simon ST, Higginson IJ, Benalia H, et al. Episodic and continuous breathlessness: a new Categorization of breathlessness. *J Pain Symptom Manage* 2013;45:1019–1029.
 10. Polkey M, Moxham J. Attacking the disease spiral in chronic obstructive pulmonary disease. *Clin Med* 2006;6:190–196.
 11. Resnick B, Spellbring AM. Understanding what motivates older adults to exercise. *J Gerontological Nurs* 2000;26:34–41.
 12. Fischer MJ, Scharloo M, Abbink JJ, et al. Drop-out and attendance in pulmonary rehabilitation: the role of clinical and psychosocial variables. *Respir Med* 2009;103:1564–1571.
 13. Bausewein C, Booth S, Gysels M, Higginson Irene J. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. *Cochrane Database of Systematic Reviews [Internet]* 2008;(2):CD005623.
 14. Coulthard M. Non-pharmacological intervention with breathless patients in a palliative care setting. Chartered Society of Physiotherapy (CSP) Congress. London: Association of chartered physiotherapists in oncology and palliative care (ACPOPC), 2004:10–12.
 15. Swan F, Booth S. The role of airflow for the relief of chronic refractory breathlessness. *Curr Opin Support Palliat Care* 2015;9:206–211.
 16. Liss HP, Grant J. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1988;137:1285–1288.
 17. Johnson MJ, Simpson MIG, Currow DC, Millman RE, Hart SP, Green G. Magnetoencephalography to investigate central perception of exercise-induced breathlessness in people with chronic lung disease: a feasibility pilot. *BMJ Open* 2015;5:e007535.
 18. Johnson MJ, Simpson M, Millman R, Green G. Magnetoencephalography as a neuro-imaging method in chronic dyspnoea: a feasibility study. *Eur Respir J* 2014;44(Suppl. 58):P670.
 19. Fletcher C. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). *BMJ* 1960;2:1665.
 20. Cambridge Breathlessness Intervention Service Patient Information Leaflets 2014. Available from: <http://www.cuh.org.uk/breathlessnessintervention-service-bis/resources>.
 21. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax* 1992;47:1019–1024.
 22. Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. *Eur Respir J* 2014;44:1447–1478.
 23. Peel C, Baker PS, Roth DL, Brown CJ, Bodner EV, Allman RM. Assessing mobility in older adults: the UAB study of aging life-space Assessment. *Phys Ther* 2005;85:1008–1019.
 24. Stalvey BT, Owsley C, Sloane ME, Ball K. The life-space questionnaire: a measure of the extent of mobility of older adults. *J Appl Gerontol* 1999;18:460–478.
 25. Baker PS, Bodner EV, Allman RM. Measuring life-space mobility in community-dwelling older adults. *J Am Geriatr Soc* 2003;51:1610–1614.
 26. Schwarzer R, Jersusalem M. Generalized Self-Efficacy Scale. In: Weinman J, Wright S, Johnston M, eds. *Measures in health psychology: a user’s portfolio. Causal and control beliefs*. Windsor: NFER-Nelson, 1995;35–37.
 27. Scherbaum CA, Cohen-Charash Y, Kern MJ. Measuring general self-efficacy: a comparison of three measures using item response theory. *Educ Psychol Meas* 2006;66:1047–1063.
 28. Gift AG, Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. *Am J Crit Care* 1998;200–204.
 29. Bédard M, Molloy DW, Squire L, Dubois S, Lever JA, O’Donnell M. The Zarit burden interview: a new short Version and screening Version. *Gerontologist* 2001;41:652–657.
 30. Higginson IJGW, Jackson D, Murray J, Harding R. Short-form Zarit Caregiver burden interviews were valid in advanced conditions. *J Clin Epidemiol* 2010;63:535–542.
 31. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ* 2016;355.
 32. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ: Br Med J* 2014;348.
 33. Browne RH. On the use of a pilot sample for sample size determination. *Stat Med* 1995;14:1933–1940.
 34. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;3:77–101.
 35. Creswell JW, Plano Clark VL. *Designing and conducting mixed methods research*. Thousand Oaks, Calif.: SAGE Publications, 2007.
 36. Luckett T, Phillips J, Johnson MJ, et al. Contributions of a hand-held fan to self-management of chronic breathlessness. *Eur Respir J* 2017;50.
 37. Maddocks M, Taylor V, Klezlova R, England R, Manderson C, Wilcock A. When will I get my breath back? Recovery time of exercise-induced breathlessness in patients with thoracic cancer. *Lung cancer* 2012;76:128–129.
 38. Farquhar MC, Prevost AT, McCrone P, et al. Is a specialist breathlessness service more effective and cost-effective for patients with advanced cancer and their carers than standard care? Findings of a mixed-method randomised controlled trial. *BMC Med* 2014;12:194.
 39. Johnson MJ, Booth S, Currow DC, Lam LT, Phillips JL. A mixed-methods, Randomized, controlled feasibility trial

to inform the design of a phase III trial to test the effect of the Handheld fan on physical activity and carer anxiety in patients with refractory breathlessness. *J Pain Symptom Manage* 2016;51:807–815.

40. Brighton LJ, Miller S, Farquhar M, et al. Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis. *Thorax* 2018; 74:270–281.

41. Harris D, Hayter M, Allender S. Improving the uptake of pulmonary rehabilitation in patients with COPD. qualitative study of experiences and attitudes. *BMJ* 2013;347:f703–710.

42. Mularski R, Reinke L, Carrieri-Kohlman V, et al. An official American Thoracic Society workshop report: Assessment and palliative management of dyspnea crisis. *Ann Am Thorac Soc* 2013;10:S98–S105.

43. Bandura A. *Self-efficacy: The exercise of control*. New York: WH Freeman and company, 1997.


44. Zwerink M, Brusse-Keizer M, van der Valk Paul D, et al. Self management for patients with chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* [Internet] 2014;(3).

45. Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. *Lancet Respir Med* 2014;2: 979–987.

46. Johnson MJ, Kanaan M, Richardson G, et al. A randomised controlled trial of three or one breathing technique training sessions for breathlessness in people with malignant lung disease. *BMC Med* 2015;13:1–11.

Appendix

Online supplementary diagram



Using the Calming Hand

1. Acceptance – Squeeze thumb and recognize that you are starting a breathless or panic attack.
2. Sigh out. Flop and Drop – relax shoulders
3. Breathe in and out slowly, gently and focus on the breath out.
4. Stretch hands fully and then let them go

You may need to repeat this several times before your breathing and anxiety start to

Calming Hand.